Adenoviral gene expression that is repressed by p53 in nontransformed cells could provide a tumor-specific gene therapy approach for a large subset of tumors. Adenoviral infection in vivo induces stabilization of p53, which can be utilized for a strategy that includes p53-dependent expression of a transcriptional repressor and a target promoter ,which is highly susceptible for transcriptional repression. Therefore, we constructed different versions of CMV-promoters (CMV gal ) with binding sites for GAL4-DBD and investigated 11 GAL4-DBD fusion proteins to elucidate the most effective repressor domain to silence CMV gal activity.The transcriptional repressor GAL4-KRAB-A under control of a p53-dependent promoter facilitates strong CMV gal -mediated gene expression specifically in p53 mutant cells by a double-recombinant adenoviral vector (Ad-RGCdR). GAL4-KRAB-A mediates strong transcriptional repression of Ad-RGCdR in p53 wild-type cells, which could be further enhanced by preactivation of p53-signalling following low-dose chemotherapy prior to adenoviral infection. By utilizing p53 signalling involved in chemotherapy and adenoviral infection, more than 99% of Ad-RGCdR gene expression could be repressed in p53 wild-type cells. Controlled gene expression from CMV gal promoters by transcriptional repression utilizing functional p53 signalling thus provides a very effective tool for tumor-specific adenoviral gene therapy.
C
ancer gene therapy has been one of the great yet unfulfilled promises of the recent years. One important limitation of cancer gene therapy is still the lack of tumor specificity. Tumor selective gene expression may provide an effective tool to target cancer cells selectively and to avoid deleterious side effects in normal tissues. Besides retargeting adenoviral vectors by genetical modifications of the fiber protein, many attempts have been made to target therapy to cancer cells by using tumor selective promoters such as AFP-, CEA-, PSA-or hTERT-promoter. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Using this approach, tumor specificity has been achieved at the cost of 50-300-fold loss in transcriptional activity compared to the strong but nonselective CMV-promoter. Other important limitations of gene therapy targeting by tumor-specific promoters are the heterogenous strength of these promoters in different tumor cells within a tumor nodule and the wide variety of promoter activities in different tumors.
A more reliable way to achieve tumor selective gene expression thus may be the repression of strong promoters in nontransformed cells by utilizing signal transduction pathways that are decisively involved in the development of cancer. Cell cycle dysregulation, loss of genomic stability, and apoptotic control are the key factors in carcinogenesis. 11 One of the most important molecules that maintain genomic stability and cell cycle control is the tumor suppressor p53. 12 Protein level and transcriptional activity of p53 is upregulated following DNA damage, viral infection, hypoxia or other factors threatening the cellular and genomic integrity. Approximately 50% of human tumors harbor genomic alterations in the p53 gene locus and lack expression of the functional p53 wild-type protein. 13 In another subset of tumors, p53 activity is inhibited by other molecular mechanisms such as complex formation of p53 with oncogenic proteins [14] [15] [16] or decreased p53 protein stability. 17 A promoter that is strongly repressed by p53 activity in normal cells could thus provide tumor-selective gene expression for the majority of human tumors.
In our study, we used mutated and truncated versions of the CMV promoter (CMV Gal ) harboring different clusters of binding sites for GAL4-DBD. Reporter gene expression controlled by these CMV promoter variants was strongly inhibited by the expression of a GAL4-KRAB-A transcriptional repressor fusion protein under control of the artificial p53-dependent promoter prMin-RGC. Double-recombinant adenoviruses containing CMV Gal /luciferase and prMin-RGC/GAL4-KRAB-A expression cassettes displayed up to 99.5% less luciferase activity in p53 wild-type cells compared to a control vector lacking the p53-dependent promoter. In contrast, both vector types showed equivalent high luciferase levels in p53 mutant cells. Furthermore, we show that repression could be enhanced by p53 preactivation through adriamycin treatment.
Materials and methods

Cell lines and plasmids
Hep3B, HepG2, Huh7, HT-1080, HT29, SAOS-2, MCF-7, A549, U2-OS, and 293 cell lines were obtained from the American Type Culture Collection. The cells were maintained in growth medium (Dulbecco's modified Eagle's medium þ Glutamax, Life Technologies Inc.) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies Inc.), 100 U/ml penicillin, and 100 mg/ml streptomycin (Seromed) at 371C in 5% CO 2 . MCF-7 cells were additionally supplied with 0.01 mg/ml insulin.
The CMV-p53wt expression vector (pC53SN3) was generously provided by Bert Vogelstein. Expression vectors for repressor fusion proteins of GAL4-DBD were kindly provided by: L Lania, Neaples, Italy (KRAB-A), 18 RA DePinho Boston, USA (m-SIN3B-SF and m-SIN3B-LF), 19 DJ Hall, Philadelphia, PA, USA (ZF87/MAZ), 20 K Bomsztyk, Seattle, USA (ZIK1), 21 LM Staudt, Bethesda, MD, USA (BCL-6), 22 C Bartholomew, Glasgow, Scotland (EVI-1), 23 Y Shi, Boston, USA (YY), 24 H-S Ro, Halifax Canada (AEBP2) 25 and A Bird, Edinburgh, UK (MeCP2 170-310 and MeCP2 209-492). 26 
Plasmid construction
CMV promoters containing internal GAL4 binding sites were generated by site directed mutagenesis (Quickchanget-kit, Stratagene) of the plasmid pBK-CMV (Stratagene) using the oligonucleotides 5
0 (Mt5-sense) and 5 0 -CCCCG-TGAGTCGGACCGCTATCCACCGCCATTGATGT-AC-3 0 (Mt5-antisense. The AseI (Klenow fill in)-NheI fragment was excised and subcloned into the vector pGL2-Basic to obtain luciferase reporter plasmids. 5 0 -Truncated forms of these mutant CMV promoters were obtained by conventional PCR using the antisense primer 5 0 -GTAATTGCGGCTAGCGGATCTGACGG-3 0 and the sense primers 5 0 -TCACCCGGGTACCATGGT-GATGCGGTTTTGGCAG-3 0 (for creating the 224 bp version of the CMV promoter), 5 0 -TCACCCGGGTAC-CAAGTACGCCCCCTATTGACGTC-3 0 (344 bp version), and 5 0 -TCACCCGGGTACCCCCGCCCATTGA-CGTCAATAATG-3 0 (474 bp version). The antisense primer contained a NheI site, the sense primers a SmaI site for subsequent subcloning of the resulting PCR fragments into the appropriate sites of pGL2-Basic. The sense primers also contained an additional KpnI site for 5 0 terminal insertion of 5 Â GAL4 binding site fragments. Those were generated from the plasmid 5 Â GAL4-Luc (M. Niehoff) by PCR using the primers 5 0 -CCGGTACCTTGCATGCCTGCAGGTCG-3 0 (sense) and 5 0 -CCGGTACCTATACCCTCTAGAGTCTCCGC-3 0 (antisense). For downstream insertion the 5 Â GAL4 fragment (XbaI(Klenow)/HindIII) was excised from 5 Â GAL4-Luc and subcloned into the HindIII and XhoI(Klenow) sites of pGL2-Basic.
For construction of the promoter prMin-RGC, the 13 Â RGC fragment was excised from the plasmid pSK-45-13-2-PyCAT (provided by B. Vogelstein) by digestion with HindIII/EcoRI followed by Klenow-fill-in and ligated with the Klenow-blunted KpnI site of pGL-2-Basic (Promega). For the downstream insertion of a CMV minimal promoter (the TATA motif is highlighted), the oligonucleotides 5 0 -GCGAGCTCGTACGGTGGGA-GGGCTATATAAGCAGACCTCGTTTAGTGAACCG-TCAGATCGCCTGGAGACGAAGCTTCCG-3 0 (antisense) and 5 0 -CGGAAGCTTCGTCTCCAGGCGATCT-GACGGTTCACTAAACGAGGTCTGCTTATATAGC-CCTCCCACCGTACGAGCTCGC-3 0 (sense) were annealed, digested with HindIII/SacI and cloned into the respective sites of pGL-2-Basic.
GAL4-KRAB-A and GAL4-mSin3B-SF expressing vectors under control of prMin-RGC were constructed as follows: the GAL4-KRAB-A containing fragment was PCR generated from the vector pZIKDBH (L. Lania) via PCR using the primers 5 0 -CCGAAGCTTACCAT-GAAGCTACTGTCTTCTATCGAACAAGC-3 0 (sense) and 5 0 -GCGATATCCTAACCCTGGGAGTTTAT-GAGTGCAAAGTTC-3 0 (antisense) and subcloned into the HindIII and SmaI of pBluescript (Stratagene). The GAL4-mSin3B-SF containing fragment was subcloned from pGAL0Sin3B-SF (R. DePinho) using the HindIII and EcoRV sites of pBluescript. The resulting plasmids were provided with a polyA signal by subcloning the BglII/XbaI fragment of pAdApt (R. Hoeben). The prMin-RGC promoter was added by subcloning the SmaI/HindIII fragment of prMin-RGC into SalI/HindIII of pBluescript finally resulting in the p53-dependent expression plasmids pRGC-KRAB and pRGC-Sin.
Bicistronic expression plasmids were generated as indicated in the figures. The repressor expression cassettes from pRGC-KRAB and pRGC-Sin were blunt-ligated into the SmaI site of pHM3. The SalI site of pHM3 was used for blunt end insertion of the luciferase reporter cassettes under control of CMV Gal -promoters described above. Both expression cassettes could be separated by insertion of nonsense DNA into the XbaI site of pHM3 p53-mediated gene silencing in Ad-vector F Kühnel et al (1.6 kb NsiI/EcoRI fragment from the plasmid pCL18 containing nonfunctional DNA from the murine caspase-8 locus, kindly provided by C. Liedtke).
Adenoviral vector construction and preparation
Recombinant adenovirus was constructed using the cloning system that has been described previously. 27 .
The viral vectors Ad-CtrlR and Ad-RGCdR were generated by ligating the PI-Sce/I-Ceu I fragments of biscistronic expression vectors described above into the respective sites of the adenoviral backbone vector pAdHM4. The resulting plasmids were partially PacI digested (due to a PacI site in the luciferase gene) and transfected into permissive 293 cells. Transfected cells were incubated until a cytopathic effect became visible. The cell layer was then pelleted at 500 g for 10 minutes, resuspended in 2 ml phosphate buffered saline and subjected to three cycles of freezing and thawing. To remove the cell debris, the suspension was centrifuged at 7000 g and 41C for 15 minutes. The supernatant was used for the subsequent preparation of high titer stocks.
For preparation of high titer viral stocks, 2 Â 10 8 293 cells at 90% confluency were infected at a multiplicity of infection (MOI) of 10. The infected cells were maintained for 3-4 days until a strong cytopathic effect could be observed and about 50% cells were detached. The cells were then collected by centrifugation and viral particles were released by four cycles of freezing in liquid nitrogen and rapid thawing at 371C. For further purification, the virus preparation was subjected twice to CsCl density gradient centrifugation. CsCl banding and determination of infectivity by viral plaquing were performed according to standard protocols. Virus preparations were stored at À201C in 25% glycerol, 10 mM Tris/HCl, pH 7.4, and 1 mM MgCl 2 .
Animal experiments and liver nuclear extracts
Pathogen-free male NMRI-nu/nu mice (age 6-8 weeks) were obtained from the Animal Research Institute of the Medizinische Hochschule, Hannover. For infection experiments, Ad5-CMVLacZ was prepared, purified and titered as described above. Prior to infection, the virus was dialyzed twice against a solution containing 10 mM Tris-HCl, pH 8.0, 1 mM MgCl 2 , 140 mM NaCl at 41C. Infection of the mice was carried out by administration of 0.25 ml virus solution into the tail vein at a total virus load of 1 Â 10 8 PFU/g body weight, calculated for about 80% transduction of liver hepatocytes. The reliability of the infection in vivo was controlled by X-gal-stained liver sections of Ad5-CMVLacZ-infected mice. At the time points indicated in the figure legends, the mice were killed and the livers were harvested for the preparation of cryonuclear extracts, respectively. Nuclear extracts were isolated from liver tissue samples as described. 28 
Electrophoretic mobility shift assays
Electrophoretic mobility shift assay (EMSA) experiments for determining the sequence-specific DNA-binding capacity of GAL4-DBD were performed using recombinant GAL4-DBD (sc-4050, Santa Cruz). A measure of 50 ng of the recombinant protein was incubated with the 32 Plabelled oligonucleotides as previously described in the Plasmid construction section. The binding buffer consisted of 25 mM HEPES (pH 7.6), 5 mM MgCl 2 , 34 mM KCl, 2 mM DTT, 0.2 mM PMSF, 1 mg of poly(dIÀdC)/ml, and 2 mg of BSA/ml. The reaction was incubated for 30 minutes on ice and subsequently separated in a 6% polyacrylamide gel. Electrophoresis was carried out for 4 hours at 300 V. After electrophoresis, the gel was dried and exposed for autoradiography.
The oligonucleotides were purchased from NAPS (Go¨ttingen, Germany). Additionally, the following oligonucleotides were used:
0 served as negative control and the GAL4-DBD consensus site 5 0 -GTACGGTGGGCGGAGGACTGTCCTCCGGCTG-GTTTAG-3 0 as positive control. The supershift was performed using the GAL4-DBD antibody sc-577 (Santa Cruz).
SDS-polyacrylamide gel electrophoresis and Western blot analysis
Protein concentrations of nuclear extracts were measured by BioRad Assay (BioRad, Mu¨nchen, Germany). Nuclear extracts (10 mg) were separated on a 10% SDSpolyacrylamide gel and blotted onto Hybond-N membrane (Millipore, Frankfurt, Germany). As primary antibody pAb240 (Dianova, Hamburg) was used. The antigen-antibody complexes were visualized using the ECL detection system as recommended by the manufacturer (Amersham, Braunschweig).
Luciferase and caspase-3 assays
HepG2-(3 Â 10 5 ) or Huh7 (6 Â 10 5 )-cells were seeded in 60 mm dishes 16 hours prior to transfection. Cells were transfected using the calcium phosphate precipitation method with an overnight incubation at 351C and 3% CO 2 or using LipofectAMINE according to the manufacturer's protocol (Life Technologies). Functional DNA was subjected to the transfections as indicated in the figure legends. Total amount of transfected DNA was adjusted to 5 mg per dish with pBluescript KS (Stratagene). Whole-cell extracts were obtained according to standard procedures 48hours (or as indicated) after transfection and measured for luciferase activity using a Berthold Lumat LB9501 according to the standard procedures. Luciferase activity was normalized by cotransfection of 0.5 mg CMVb-gal. For the determination of caspase-3 activity in transfected cells, the BD ApoAlert Caspase Fluorescent Assay Kit (BD Biosciences) was used according to the manufacturer's protocol. Figure 1a . These results demonstrate that the cellular entry of a nonreplicative adenoviral vector provides a sufficient impact to activate p53-dependent cellular responses. The results furthermore suggest that p53 could be used as a signal transduction pathway to silence adenoviral gene expression from an appropriate promoter in untransformed cells. Tailoring adenoviral p53-dependent cancer-specific gene expression with this strategy requires p53-dependent expression of a transcriptional repressor in combination with a strong target promoter which is highly susceptible for transcriptional repression as schematically drawn in Figure 1b .
Construction of a panel of CMV-promoters (CMV gal 1-13) that are highly susceptible for transcriptional repression by GAL4-DBD-repressor fusion proteins A strong constitutional active promoter which is highly susceptible for targeted transcriptional repression is an important element of the strategy described above. The CMV promoter has been reported to be the strongest constitutional active promoter available. According to DNA footprint analysis of the CMV promoter, 29, 30 five different regions that do not interfere with known binding sites for transcription factors but are closely located to the transcriptional core of the promoter were selected for sitedirected mutagenesis. These changes resulted in internal GAL4-binding sites (indicated as Mt1 -Mt5 in Fig 2a) . For GAL4, the palindromic CGG triplets at the termini of the 17-bp recognition site and to a lesser degree the A/T at position 9 are essential for tight binding. The positions between these motives are thought to be much less important consistent with the DNA-bound GAL4-DBD crystal structure. [31] [32] [33] To evaluate GAL4 binding to putative new recognition sites of Mt1-5 in vitro, gel shift experiments were performed (Fig 2a and b) . However, only three of the five oligonucleotide duplexes tested bind recombinant GAL4-protein in vitro. Comparing the sequence of these oligonucleotides with the GAL4 consensus motif suggests that also the Pu/Py arrangement of the inner 11 bp contributes more to GAL4 binding than expected. Subsequently, nucleotides of these three regions in the CMV promoter were changed by site-directed mutagenesis (underlined and bolt in Fig 2a) to obtain three internal active GAL4 recognition sites within the transcriptional core of the CMV promoter (Fig 2c) . Neither one of the three mutations nor the combination of all three GAL4-binding sites (CMVmt1/2/5) reduced the constitutional activity of the CMV-promoter significantly (Fig 2d) . Cotransfection of a plasmid expressing a GAL4-transcriptional repressor fusion protein (GAL4-mSIN3B-SF) decreased the transcription level of CMVmt1/2/5 to a level of 33-36% compared to the CMV wild type (Fig 2d) . In this assay setup, the maximum repression could be achieved by adding just 50 ng of repressor plasmid and was not further increased by higher amounts of repressor indicating saturation of the three GAL4-binding sites by low amounts of GAL4-transcriptional repressor fusion protein.
To further enhance the susceptibility of CMV gal to transcriptional repression, we cloned a pattern of 13 different CMV gal -promoters (CMV gal 1-13 ) by adding clusters of 5 Â GAL4 binding sites up-and downstream of full-length and truncated versions of CMVmt1/2/5 (Fig 3a) . Promoter manipulations resulted in reduced constitutional activity ranging from 80 to 10% compared with the CMVwt promoter activity (Fig 3b) . All tested promoter constructs displayed a significant reduction of activity when GAL4-DBD fusions of KRAB-A or Figure 1 Adenoviral infection in vivo induces p53-protein expression. Nuclear extracts were isolated from mouse livers at the indicated time points after systemic infection with AdCMVLacZ by tail vein injection. Western blot analysis demonstrates the upregulation of p53 protein expression (a). As a positive control for Western blotting nuclear extracts from Hep3B cells were used that were transfected with the p53 expression plasmid pC53SN3. (b) Schematic diagram of the strategy of tumor-specific gene expression by p53-dependent transcriptional repression. In p53 wild-type cells, a repressor under the control of a p53-responsive promoter (here: p53-dep-Pr) inhibits gene expression of an artificial promoter (here: rs-promoter) that controls a therapeutic gene, whereas constitutive promoter activity of the rs-promoter is not repressed in p53-defective tumor cells.
p53-mediated gene silencing in Ad-vector F Kühnel et al mSIN3B-SF were cotransfected. The extent of reduction was largely dependent on the number of inserted GAL4 sites (Fig 3c) . GAL4-recognition sites inserted downstream of the CMVmt1/2/5-promoter significantly decreased the constitutional promoter activity (up to 50% ,  Fig 3b) , but using GAL4-KRAB-A as repressor they mediated transcriptional repression more effectively compared to upstream GAL4 binding sites (Fig 3c) . This difference was diminished when upstream GAL4 binding sites were more closely located to the transcription start due to promoter truncation. These findings are in consistence with reports that the repressor KRAB primarily affects the basal transcription machinery. 34 Comparable results could be observed using the p53 mutant or deleted cell lines Huh7 and Hep3B, respectively, showing that the activity and repression properties of CMV gal 1-13 were not cell-type specific or dependent on the p53 status (data not shown). Taken together, the promoter constructs CMV gal 1-13 represent different activities ranging from 80 to 10% compared to the CMVwt promoter and defined repression susceptibilities that may be useful for different tumor gene therapeutic approaches.
The promoters most susceptible for transcriptional repression were CMV gal 5 , CMV gal 8 , CMV gal 11 ,and CMV gal 13 ( Figure 3c ). Even by adding very low amounts (5-250 ng) of repressor expression plasmid encoding the transcriptional repressor proteins GAL4-mSIN3B-SF (Fig 3d) or GAL4-KRAB-A (data not shown), the activity of 1000 ng of CMV gal reporter plasmid was reduced to the level of 1-8% of the constitutional strength in Hep3B cells.
GAL4-mSIN3B-SF and GAL4-KRAB-A are the most active transcriptional repressors of CMV gal -promoters Transcriptional repression is mediated by different molecular mechanisms, such as promoter methylation, histone deactylation, or modulation of transcription factors. To identify the most active transcriptional repressor domain suitable for GAL4-mediated repression of CMV gal , we investigated a panel of different GAL4-repressor domain fusion proteins. Low amounts of expression plasmids coding for GAL4-DBD-repressor fusion proteins were cotransfected with CMV gal 13 reporter plasmid and transcriptional repression was assessed by luciferase assay (Fig 4a) . The most powerful transcriptional repressors of CMV gal 13 were GAL4-mSIN3B-SF and GAL4-KRAB-A.
The strategy of tumor-specific gene expression presented in this study involves p53-dependent overexpression of GAL4-repressor proteins. Since overexpression of transcriptional repressors could result in cytotoxicity, we investigated the effect of GAL4-mSIN3B-SF and GAL4-KRAB-A after transfection of high amounts of the respective expression plasmids in Huh7 cells p53-mediated gene silencing in Ad-vector F Kühnel et al (Fig 4b-d) . In contrast to GAL4-mSIN3B-SF, GAL4-KRAB-A showed no cytotoxicity as shown by X-gal staining and proliferation assay (Figures 4b and c) . Furthermore, a strong caspase-3 activity could be observed after GAL4-mSIN3B-SF cotransfection indicating that this repressor might be an inductor of an apoptotic process (Figure 4d) . Similar results were observed in Hep3B cells (data not shown).
The strong artificial promoter prMin-RGC is highly selective for transcriptional activation by functional p53
For p53-dependent expression of GAL4-KRAB-A or GAL4-mSIN3B-SF, we constructed the prMin-RGC promoter containing 13 p53-binding sites in combination with a minimal CMV-promotor providing the TATA-Box motif. The transcriptional properties like inductional strength and p53 selectivity of prMin-RGC were then compared with counterparts containing p53 consensus binding sites (prMin-4C and prMin-8C, Fig 5a) . Using luciferase reporter plasmids, inductional strength was measured by transfection experiments in p53wt-HepG2 cells with or without additional adriamycin treatment and by cotransfection of ectopic p53 in p53À/ À Hep3B cells (Fig 5b) . prMin-RGC displayed significantly stronger activity due to the transfection stress compared to the consensus promoters. Additional p53 stimulation by adriamycin leads to an increase in luciferase expression controlled by the consensus promoters suggesting that prMin-RGC is more sensitive to p53 activity than the consensus counterparts. The number of p53-binding sites seemed to play a minor role in these assays. Furthermore, prMin-RGC showed high transcriptional activity upon activation by p53 associated with high selectivity for wt p53 (Fig 5c) . Alone or in the presence of nonfunctional p53 mutant proteins this promoter remained completely silent, whereas the consensus promoters prMin-4C and -8C displayed a significant background activity. Altogether, these data indicate that the promoter prMin-RGC meet the requirements for p53 selective gene expression.
Generating of recombinant double transgene adenoviral vector with tight p53-dependent regulation of gene expression
As transcriptional repression by GAL4-KRAB-A could not only inhibit the activity of the target CMV gal promoter, but also the activity of the p53-dependent promoter prMin-RGC by trans-acting mechanisms, we then investigated whether the distance and the orientation of two respective expression cassettes would influence p53-dependent gene expression in a double transgene expression plasmid. The p53-dependent transcriptional repressor cassette and the CMV gal reporter cassette were therefore subcloned into an adenoviral shuttle vector in different orientations (Fig 6a) . To investigate the effect of local promoter interference on the transcriptional repression of CMV gal , a noncoding DNA spacer was inserted between reporter and repressor cassettes. 
p53-mediated gene silencing in Ad-vector F Kühnel et al
As demonstrated in Fig 6b, orientation of the expression cassettes modulated p53-dependent repression of CMV gal . Interestingly, a correlation of orientation with both GAL4-KRAB-A-and GAL4-mSIN3B-SF-mediated transcriptional repression could be observed. In addition to the aspect of orientation, separation of the two expression cassettes appears to be necessary to obtain maximal susceptibility to p53-mediated transcriptional repression. Direct neighborhood of the two promoters largely decreased the extent of repression.
For generating double transgene adenoviral vectors, we used the adenoviral shuttle plasmid displaying the most effective p53-dependent repression in transfection experiments (r-s-r GAL4-KRAB-A). p53-dependent adenovirus (Ad-RGCdR) and a corresponding non-p53-dependent control adenovirus lacking the prMin-RGC promoter (Ad-CtrlR) were generated (Fig 6a) .
p53-dependent adenoviral gene expression was first characterized in p53wt (HepG2) and p53 mutated Huh7 cells by luciferase assays. As demonstrated in Figure 7a adenoviral GAL4-KRAB-A expression by prMin-RGC (Ad-RGCdR) leads to a strong p53-dependent transcriptional repression of CMV gal 11 . In contrast, CMV gal 11 -controlled luciferase expression was strong following infection of HepG2 cells with the control virus Ad-CtrlR lacking the prMin-RGC promoter for GAL4-KRAB-A expression. After infection of p53-mutant Huh7 cells, both adenovirus types showed equivalent luciferase expression indicating that repression occurs in a p53-dependent manner. The applied MOI seemed to have a Figure 5 Construction and characterization of the p53 dependent promoter prMin-RGC. prMin-RGC is strongly induced by p53 and is highly selective for functional p53. (a) Construction of different putative p53 dependent promoters consisting of a CMV minimal promoter (resembling the TATA motif) and p53-binding sites. (b) HepG2 cells (wt-p53) and Hep3B were cotransfected with 1 mg of luciferase reporter constructs under control of artificial p53-dependent promoters as indicated and with 0.3 mg of pCMV-LacZ. Adriamycin was added in a concentration of 200 ng/ml when transfection was finished. In p53-deleted Hep3B cells, ectopic p53 expression was achieved by cotransfection of 50 ng of the vector pC-53-SN3. At 36 hours after transfection, cells were harvested and luciferase activities were assessed and normalized against -gal expression. (c) Hep3B were cotransfected and assayed as described above. Ectopic expression of transcriptionally inactive p53 mutant proteins was achieved by cotransfection of 50 ng of the plasmids pC-SN3-220C, pC-SN3-249S, pC-SN3-249M or pBluescript as negative control.
p53-mediated gene silencing in Ad-vector F Kühnel et al minor impact on the observed extent of repression. In contrast to the constitutional CMV promoter activity, prMin-RGC needs activation through p53 signal transduction pathways. High levels of p53 protein can be observed 8 hours following the genotoxic impact such as transfection or adenoviral infection (see above). As simulated by the luciferase assay shown in Fig 7b, this leads to a transcriptional delay of prMin-RGC activity in the early time course after cellular entry compared to CMV-promoter. This time lack may result in unrepressed CMV gal promoter activity directly following the adenoviral infection and thus may enhance background gene expression in normal p53 wt cells. On the other hand, this observation suggests that the steady-state repression upon p53 activation might be even higher as demonstrated in these assays and that the replacement of the luciferase reporter by therapeutic transgenes with a shorter half-life may result in even lower background levels.
To achieve higher p53-dependent specificity, we activated p53 signalling prior to adenoviral infection to compensate the time lack of prMin-RGC activity. This was accomplished by adding the p53-activating chemotherapy agent adriamycin 8 hours before the target cells were infected. As shown in Figure 7a , reporter expression of Ad-RGCdR in p53 wt cells dropped to less than 1% of the luciferase activity of the control vector Ad-CtrlR after preactivation of p53 by low-dose adriamycin treatment. This represents an up to five-fold enhancement of the repression extent compared to the assays without adriamycin pretreatment. These results suggest that the effectivity of the repression system presented here can be further enhanced by combination with low dose of conventional chemotherapy.
To exclude cell line-specific effects, we further tested additional cell lines in a comparable assay setup with or without adriamycin treatment. Those were the p53 mutant cell line HT29, the p53-deleted cell lines SAOS-2 and Hep3B. MCF-7, U2-OS, HT-1080, and A549 represent p53 wt cells. As shown in Figure 7c , the p53-dependent repression system functioned in all p53 wt cell lines tested. However, the extent of repression varied from 11-fold (U2-OS cells without adriamycin pretreatment) to more than 1000-fold (A549/ þ adriamycin). p53-mutated or -deleted cell lines displayed no significant repression suggesting that the adenoviral repressor system works strictly dependent on the function of p53. Furthermore, in all p53 wt cell lines the efficacy of repression could be improved by application of adriamycin.
Discussion
The application of novel tumor therapies depends on effective means of selective tumor targeting. The p53 signal transduction pathway is one of the most interesting targets for cancer therapy, because the majority of human tumors harbor p53 mutations, p53 gene deletions, or other molecular alterations that inhibit p53-mediated cell response. Additionally, it has been demonstrated that p53 mutations are correlated with resistance to chemotherapy in some tumors and with poor prognosis of the patients. [35] [36] [37] In particular, for those tumors new cancer therapies based on other molecular mechanisms than conventional chemotherapy are urgently needed.
Gene therapy is a powerful tool that holds promise for the treatment of cancer. Adenoviruses have emerged as potent vectors for tumor gene therapy since they have the ability to transduce dividing and nondividing cells in a variety of epithelial tumor tissues. But it has also been shown that lack of tumor specificity of high-dose adenoviral gene therapy can result in severe toxicity, [38] [39] [40] which would necessitate research on new strategies to achieve clinical efficacy combined with less toxicity.
Some studies demonstrate that tumor specificity can be improved by receptor-retargeting or by construction of viral vectors with tumor-specific promoters. [1] [2] [3] [4] [5] [6] [7] [8] [9] [41] [42] [43] [44] [45] [46] In p53-mediated gene silencing in Ad-vector F Kühnel et al addition, it has been shown that combined transductional and transcriptional targeting strongly improves specificity of transgene expression in vivo. 47 However, only few studies investigated p53-dependent signal transduction pathways to achieve tumor-specific gene therapy. Mutated adenoviral vectors that are unable to bind p53 have been designed to replicate selectively in p53-defective tumor cells, whereas productive infection of these vectors in normal cells is repressed by intact p53-pathways. 48 These strategies appear to be convincing but some conflicting data exist about the actual p53 specificity of these vectors. p53-dependent replication has been demonstrated in hepatocellular carcinoma cells only at low MOI, but not at high MOI. 49 It appears that differences in oncolyis may be due to infectivity or permissiveness, rather than p53 status of the investigated tumor cells. [50] [51] [52] Recently, two other studies investigated p53-dependent transcriptional repression to obtain tumor selectivity. Lipinski et al described a double-recombinant adenoviral vector encoding a therapeutic gene, driven by the hsp70 promoter, which is indirectly repressed by endogenous p53 wild type. However, this vector expressed only 70% less therapeutic protein in p53 wild-type cells compared to a control vector. 53 The elegant strategy of p53-dependent expression of the fusion protein E2F-Rb, described by Ramachandra et al, 54 targets transcriptional repression to the host genome to inhibit adenoviral replication, but do not facilitate p53-dependent expression of therapeutic transgenes. Therefore, p53-dependent gene therapy strategies described so far lack high specific transgene expression in p53-deficient cancer cells.
We constructed a panel of CMV promoters that are highly susceptible for transcriptional repression mediated by GAL4-repressor fusion proteins. In addition, different fusion proteins were investigated to obtain the most effective transcriptional repression domain for CMV galpromoter silencing. KRAB-A and mSIN3B-SF were the most active domains to silence the CMV gal promoter activity in our experiments. In transcriptional repression many molecular mechanisms are involved, such as promoter methylation, histone acetylation, or modulation of proteins of the basal transcription machinery, which are represented in the different investigated Figure 7 The high specificity of adenoviral gene expression in p53-defective cells can be enhanced by activation of p53 signalling by low-dose chemotherapy prior to adenoviral infection. (a) p53-defective (Huh7) and p53 wt (HepG2) cells were infected at low and high MOI with p53-dependent adenoviral vector (Ad-RGCdR) and control virus lacking the prMin-RGC promoter (Ad-CtrlR). (b) Luciferase activity was assessed 6 hours after infection and p53-dependent adenoviral gene expression of Ad-RGCdR was demonstrated. Preactivation of p53 signalling through low-dose chemotherapy (Adriamycin 200 ng/ml medium) 8 hours before adenoviral infection enhanced significantly p53-dependent transcriptional repression in Ad-RGCdR-infected cells. The calculated repression (nfold) is given in boxes. Luciferase activity was assessed in the time course after cotransfection of HepG2 cells with 1 mg of CMV-and prMin-RGC luciferase reporter plasmids suggesting a delayed transactivation of prMin-RGC compared to CMV. Delay of prMin-RGC activity would result in undesirable background of CMV gal activity in untransformed cells after Ad-RGCdR infection. (c) Several p53 mutant (Huh7, HT29), deleted (SAOS-2, Hep3B), or wild-type cells (MCF-7, HT-1080, U2-OS, and A549) were infected with AdRGCdR or Ad-CtrlR at an MOI to achieve a degree of infection comparable to MOI 5 in HepG2 cells. The p53 status is also provided in the figure in parenthesis. At 48 hours following infection, luciferase measurements demonstrated that the p53-dependent repressor system functions in a variety of cell lines. The calculated repression (n-fold) is presented in boxes.
p53-mediated gene silencing in Ad-vector F Kühnel et al domains. [18] [19] [20] [21] [22] [23] [24] [25] [26] 55, 56 The KRAB-domain represses the activity of CMV-promoter through direct communications with TATA box-dependent basal transcription machinery, 18 ,55 whereas mSIN3B interacts with essential DNAbinding proteins that place it in a promoter context in which it can repress transcription by recruiting proteins that condense chromatin by histone deacetylation. 19 In contrast to KRAB-A or mSIN3B, the Zik1-repressor domain does not repress gene transcription from the CMV gal -promoter and some of the other repressor domains showed only weak repression of CMV galactivity. These results may be explained by different molecular mechanisms of gene silencing in distinct promoters and indicates that the arrangement of promoter elements, even in the context of strong repressor domains, can profoundly influence the mechanisms of transcriptional repression.
In our double-recombinant adenovirus Ad-RGCdR, expression of GAL4-KRAB-A is mediated by a p53-dependent promoter, which in turn restricts CMV gal promoter activity to p53-defective cells. Up to more than 99% of CMV-mediated gene expression is repressed in p53 wt cells after activating p53 signalling by low-dose chemotherapy and subsequent adenoviral infection. The principle was further confirmed in a variety of cell lines using p53-mutated or -deleted cells as well as p53 wt cells to exclude cell line-specific effects. Furthermore, these results demonstrate a level of tumor specificity that has not been reached even by weaker tumor-specific promoters, such as CEA, AFP, PSA, or hTERT. In addition, it is important to note that high p53 specificity of adenoviral gene expression has been observed not only at low MOI, but also after high-dose adenoviral infection, which is an important safety issue for clinical studies.
In contrast to the other tumor-specific gene therapy strategies, application of Ad-RGCdR results in high-level gene expression in p53-defective cancer cells with very low background levels of less than 1% in wt-p53-expressing cells. In addition to tumor-specific gene expression of therapeutic genes, the described strategy of p53-dependent promoter controlled repression should be valuable for other p53-tailored gene therapy approaches, such as p53-dependent expression of suicide genes or p53-dependent viral replication, to improve the specificity and efficacy of gene therapy.
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